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Abstract
Objective: This study used nationwide data to determine the prevalence of self-monitoring of blood glucose
(SMBG) among all non-institutionalized persons living in Norway and to estimate the prevalence of SMBG
among diabetes patients, the frequency and cost of SMBG, and the use of different glucometers.
Methods: This retrospective, descriptive study is based on data of sales of glucometer strips to non-
institutionalized persons in Norway in 2008. The data included gender, age group, month of purchase, sales
place, type of strips, number of packages dispensed, and cost of strips. Additionally, statistics on sales of insulin
and oral antidiabetes medications were obtained from the Norwegian Prescription Database.
Results: A total of 96,999 persons purchased strips, a prevalence of 2%. Approximately 70% of diabetes patients
practiced SMBG. An average patient used 1.7 strips per day, and younger patients purchased more strips than
older patients. Fewer than 50% of patients performed glucose measurements daily. One percent of patients used
more than 10 strips daily and was accountable for 8% of total costs. Most patients used only one type of strips,
but the number of strips purchased increased with the number of different strips. The average annual cost of
strips was 446 e per person.
Conclusions: Two percent of all non-institutionalized inhabitants and an estimated 70% of patients using dia-
betes medication purchased SMBG strips. A small percentage of the patients incurred a substantial proportion of
the costs. This, along with the fact that over half of the patients monitor less than once per day, calls for tighter
follow-up of diabetes patients.
Introduction
After the Diabetes Control and Complications Trial
1
and the United Kingdom Prospective Diabetes Study2
showed the beneﬁts of stringent glucose control for both pa-
tients with type 11 and type 22 diabetes, self-monitoring of
blood glucose (SMBG) has been widely recommended by
patient and professional organizations as an integral part of
the management of diabetes.3–5 However, few studies have
investigated the extent and costs of diabetes patients’ use of
SMBG in their day-to-day management of diabetes.6–8
Worldwide annual cost of SMBG is estimated to be over
$5 billion US, with a yearly growth rate of 11.5%.9 Neither
prevalence of SMBGnor frequency ofmeasurements iswidely
studied. Published work often consists of small-scale studies
of selected patient groups (e.g., patients with type 1 diabetes,6
seniors in Nova Scotia7), and thus the ﬁndings are difﬁcult to
extrapolate to entire populations of diabetes patients. One
notable exception is a study performed by theNational Center
for Chronic Disease Prevention and Health Promotion in
North America, using random-digit-dialed telephone survey
of the non-institutionalized, U.S. civilian population aged
> 18 years to investigate the rate of patients with diabeteswho
performed SMBG at least once per day. It found that in 2006
the daily SMBG ratewas 63.4% among all adultswith diabetes
and 86.7% among those treated with insulin.8
There generally seems to be agreement among researchers,
clinicians, and patient organizations that all patients who use
insulin should perform SMBG,8–10 but there is not agreement
on whether patients not using insulin beneﬁt from SMBG at
all.11–16 Also, it is difﬁcult to deﬁne limits for under- or
overconsumption of strips, or to deﬁne what the ‘‘correct’’
frequency of measurement should be, as most guidelines are
vague on these issues, especially regarding patients who do
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not use insulin.5 Bergenstal and Gavin10 have published
guidelines on behalf of the Global Consensus Conference on
Glucose Monitoring Panel that specify different frequencies
depending on how well the patient’s blood glucose is regu-
lated and the patient’s use of medication, but the evidence
underlying these recommendations is not strong, and the
newly published Norwegian diabetes guideline4 does not
suggest a recommended frequency of measurement.
The aim of this study was to use complete nationwide data
to determine the prevalence of SMBG among all non-
institutionalized persons living in Norway. Furthermore, we
wished to estimate the prevalence of SMBG among diabetes
patients, the frequency and cost of SMBG, and the use of
different glucometers.
Subjects and Methods
All Norwegian residents and persons employed and
working in Norway are compulsorily ensured under the
National Insurance Scheme, funded through national tax
systems. This covers certain prescribed medication and
medical supplies for patients suffering from chronic illnesses
such as diabetes. All reimbursed sales of blood glucose strips
in Norway are reported to The Norwegian Health Economics
Administration (HELFO), a subordinate institution directly
linked to the Norwegian Directorate of Health.17
We received data from HELFO on all instances where in-
dividual patients had prescriptions dispensed on strips in
2008. The variables included gender, age group (under 15, 15–
29, 30–44, 45–59, 60–74, and 75 years or older), sales place,
month of purchase, type and number of strips purchased, and
cost of strips. HELFO replaced personal identiﬁcation num-
bers with an anonymous ID code, so that each individual’s
purchase pattern could be traced.
Furthermore, we extracted national data on sales of insulin
and oral antidiabetes medications from the Norwegian Pre-
scription Database (NorPD) at the Norwegian Institute of
Public Health,18 with the following variables: ATC code
(A10A [insulin and analogs] and/or A10B [blood glucose-
lowering drugs except insulins]), age group (10-year inter-
vals), gender, number of users, number of users per 1,000
inhabitants, and costs.
Strips bought by hospitals or nursing homes are excluded
from both the data from HELFO and from NorPD. Statistical
analysis was performed using SPSS version 15 (SPSS, Inc.,
Chicago, IL) or Microsoft (Redmond, WA) Excel. One-way
analysis of variance was used to compare means.
Results
A total of 96,999 different patients collected strips in
Norway in 2008, i.e., 2% of the Norwegian population. Only
2% of strips were purchased outside of pharmacies. Therewas
a small but signiﬁcant gender difference in the average daily
Table 1. Number of Patients and Average
Number of Strips Bought per Person
per Day by Age Group and Gender
Age group
(years) Gender
Number
of patients
Number
of strips per
day per persona
Under 15 Female 907 6.5 (6.2–6.7)
Male 950 6.5 (6.2–6.7)
15–29 Female 2,462 3.0 (2.9–3.2)
Male 2,421 3.0 (2.9–3.2)
30–44 Female 5,691 2.3 (2.2–2.4)
Male 6,057 2.3 (2.2–2.4)
45–59 Female 9,992 1.7 (1.7–1.8)
Male 13,794 1.6 (1.5–1.6)
60–74 Female 15,326 1.4 (1.4–1.4)
Male 19,073 1.3 (1.3–1.3)
75 or older Female 11,360 1.2 (1.1–1.2)
Male 8,966 1.1 (1.1–1.1)
Total 96,999 1.66 (1.65–1.68)
aMean (95% conﬁdence interval).
FIG. 1. Cumulative numbers of persons buying strips in each age group by number of strips per person per day.
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use of strips. Women used on average of 1.71 strips per day
(conﬁdence interval [CI]¼ 1.69–1.74), and men used on av-
erage 1.62 strips per day (CI¼ 1.60–1.64). Younger patients
purchased signiﬁcantly more strips than older patients
(Table 1) (one-way analysis of variance, P< 0.001).
Of all the patients in our study, 45%purchased enough strips
to monitor glucose daily. Among patients under 30 years old,
77% purchased enough strips for daily SMBG. Figure 1 shows
the cumulative percentage of patients for each age group. One
percent of the patients used more than 10 strips per day, in-
curring 8% of the total costs, and 272 people bought more than
5,000 strips (i.e., 100 packages of 50 strips) in 2008.
Table 2 shows the number of patients who purchased blood
glucose strips compared to the number of patients taking in-
sulin, oral antidiabetes drugs (OADs), and insulin and/or
OADs and the corresponding costs per group. A total of
138,749 individuals purchased insulin and/or OADs in 2008,
corresponding to 2.9% of the population. Thus, if we exclude
patients being treated nonpharmacologically for their diabe-
tes and assume that all patients who receive reimbursement
for SMBG have diabetes, in average 70% of patients using
insulin and/or OADs were practicing SMBG. In the under 30
years age group, 85% of the number of patients who pur-
chased insulin and/or OADs purchased strips. However, of
the patients using OADs, 1,226 of 1,486 were women, and it is
likely that this large gender difference can be explained by the
fact that metformin (the OAD used by 98% of these women) is
also used in the treatment of polycystic ovary syndrome. If
one attributes the difference in prevalence between men and
women to this and extracts it from the total number of patients
treated with insulin and/or OADs, 97% of diabetes patients
under the age of 30 years perform SMBG. In total, 43,250,681
ewas spent on glucometer strips, 41,081,316 e on insulin, and
14,525,420 e on OADs.
In 2008 there were four main manufacturers providing
glucometers for the Norwegian market, and the sale was
distributed among 13 different types of reimbursable strips.
Roche (Basel, Switzerland) and Bayer Diabetes Care (Le-
verkusen, Germany) each covered 36% of the market, Abbott
Diabetes Care (Abbott Park, IL) 18%, and LifeScan (Milpitas,
CA) 10%. The majority of the users (82.3%) bought only one
type of strips, and the average number of strips used per day
increased with number of different types of strips (Table 3)
(one-way analysis of variance, P< 0.001).
Discussion
Prevalence and frequency of SMBG
To our knowledge this is the ﬁrst study to investigate the
use of strips by recording all sales of strips in a country. Other
studies investigating occurrence of SMBG have used patient
interviews or questionnaires on selected population sam-
ples.6,7,19 The prevalence of SMBG in our population was 2%.
Unfortunately, we do not have data on whether the patients
have type 1 diabetes or type 2 diabetes, nor do we know if a
speciﬁc patient uses insulin and/or OAD, but using the data
from the NorPD we can estimate that 70% of patients with
diabetes practice SMBG. In the under 30 years age group we
assume that the majority have insulin-dependent diabetes,
and this is conﬁrmed by studying the data fromNorPD.18 It is
likely that the majority of the patients in this age group who
use insulin also practice SMBG, while the majority of patients
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using OAD are women being treated for polycystic ovary
syndrome with metformin, which does not require SMBG.
OADs other than metformin could be used for indications
other than diabetes, such as thiazolidinediones for fatty liver
and exenatide for weight loss, but as diabetes is the only re-
corded indication for these drugs in Norway we assume that
any effect of this on our results is negligible. Among the pa-
tients in our study who are under 30 years old, 77% purchase
enough strips to monitor glucose daily. Among insulin users
in aNorthAmerican study, 86.7% of patients over 18 years old
performed SMBG at least once per day.8
Of all the patients in our study only 45% purchased enough
strips to measure blood glucose at least once daily, and 10%
purchased only one package (50 strips) per year. However,
the true percentage of patients who practiced daily SMBG
may be even lower because patients did not necessarily use all
the strips they purchased. Thus frequency of SMBG is low
compared to the results of the North American study from
2006 where the daily SMBG rate was 63.4% among all adults
with diabetes.8 A cross-sectional Danish–British multicenter
survey from 1999–2000 showed that SMBG was performed
daily by 39% of patients with type 1 diabetes and less than
weekly by 24%,6 while Hanko et al.19 studied patients with
type 2 diabetes visiting 14 Hungarian pharmacies in the
spring of 2004 and found that 43.6% of the patients did not
practice SMBG at all and 81% of the patients who did practice
SMBG did so less than once per day. The guidelines of Ber-
genstal and Gavin10 recommend SMBG from one or more
times daily for patients taking oral agents alone to three or
more measurements per day for patients receiving multiple
daily insulin injections or using an insulin pump.
Our ﬁnding that 1% (approximately 1,000 patients) pur-
chase enough strips to measure their blood glucose 10 times
or more every day throughout the entire year indicates
overconsumption, or at least overpurchasing, of glucometer
strips. Reasons for frequent measurements may include truly
poor glycemic control, that the patients feel insecure and
perform SMBG ‘‘just to check,’’ or poor training in correct use
of SMBG, and these patients should receive better follow-up.
They may need medication adjustment or further training
in performing SMBG and use of SMBG results. Individual
or joint efforts from general practitioners, diabetes nurses,
and/or pharmacists are alternatives to be considered as
well as training and information through diabetes patients’
organizations.
Approximately 270 patients purchased more than 5,000
strips in 1 year, equivalent to 100 packages, i.e., 14 strips per
day. One cannot exclude that these patients may share strips
with others or sell them nationally or internationally. Alter-
natively, the sales placemay enter false sales on their own or in
cooperation with general practitioners in order to falsely claim
reimbursement.20,21While we assume that this is not common,
the costs for these 270 patients add up to almost 1.3 million
e for one year, or roughly 4,800 e per person, 10 times the
average costs per person. Systematic approaches to ‘‘high-
cost’’ patients directly from HELFO, through the patients’
general practitioners, might be an option to address excessive
use of strips. Also, the general practitioners writing prescrip-
tions should indicate a maximum number of strips on each
prescription rather than writing ‘‘for 1 year’s use’’ as is often
the case today. If the patient should need more than this
amount he would have to return to his general practitioner for
follow-up, and any misunderstandings or problems could be
identiﬁed.
Changing glucometers
While glucometer strips are reimbursed by the National
Insurance Scheme, the glucometers themselves are not.
However, it is common practice for the manufacturers to
charge a token amount of money or give them away for free.
This has lead to some concern among health professionals that
patients use many different glucometers or change gluc-
ometers frequently. Both because of systematic deviations
between glucometers and more possibilities for user errors, it
may be unfortunate if a patient uses different glucometers
simultaneously, especially if these are not the same type of
meter.22 In our study we found that 18% of patients bought
more than one type of strips, but we cannot tell from our data
if this is because the patients changed their glucometer or if
they used several instruments simultaneously. However, we
can see that those who buy different types of strips purchase
more strips. At least some of these patients would most likely
also beneﬁt from counseling on their use of SMBG, performed
by general practitioners, diabetes nurses or at the pharmacies
where they purchase their strips.
Conclusions
The prevalence of SMBG in the non-institutionalized Nor-
wegian population was 2%, while approximately 70% of
diabetes patients purchased strips. More than half of the
patients do not adhere to the international recommendation10
of performing SMBG at least once per day. The average an-
nual cost of strips was 446 e per person. The 1% of patients
who have the highest purchase of strips are responsible for 8%
of the costs. Most patients use only one type of strips, but the
number of purchased strips increased with the number of
different strips.
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Table 3. Use of Different Types of Self-Monitoring
of Blood Glucose Strips by Number of Patients
and Mean Number of Strips Used per Day
Number
of different
types of strips
Number
of patients (%)
Mean number
of strips
per day
1 79,837 (82) 1.4
2 14,571 (15) 2.8
3 2,171 (2.2) 4.5
4 343 (0.4) 6.4
5 62 (0.1) 7.2
6 14 (0.0) 9.5
7 1 (0.0) 7.0
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